New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland ...

With biotech venture funding down 40% from peak levels and investor selectivity at historic highs, operational expertise has ...

As investigations into Epstein’s network persist, including scrutiny of associates like Ghislaine Maxwell, convicted in 2021 ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

From penetrating solid tumors to new success rates for de novo design, the next wave of antibody therapies aims to transform the clinic.

Polaryx believes the addition of Dr. Berger, Mr. Braun, and Dr. Ryan brings valuable expertise across scientific research, ...

As federal policymakers weigh potential changes to how biomedical research is funded and regulated in the United States, a ...

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells. However, to be effective, the new gene must make it into a cell's nucleus. The ...

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

GEN Edge recently discussed the U.S. life sciences commercial real estate market with Matthew Gardner, CBRE Americas Life Sciences Leader, in an interview conducted before the recent J.P. Morgan 44th ...

Researchers in UConn's College of Agriculture, Health and Natural Resources have developed a novel line of bovine embryonic ...

Plant cell cultures are an attractive alternative to cultivating whole plants for obtaining natural compounds, but many ...